CA57653/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1993	1
1994	2
1996	1
1998	2
1999	3
2000	4
2001	3
2004	5
2005	3
2006	2
2008	2
2009	2
2010	2
2011	3
2012	1
2014	1
2024	0

1

Thompson LW, Brinckerhoff L, Slingluff CL Jr. Thompson LW, et al. Curr Oncol Rep. 2000 Jul;2(4):292-9. doi: 10.1007/s11912-000-0021-0. Curr Oncol Rep. 2000. PMID: 11122856 Review.

2

Melanoma vaccines.

Brinckerhoff LH, Thompson LW, Slingluff CL Jr. Brinckerhoff LH, et al. Curr Opin Oncol. 2000 Mar;12(2):163-73. doi: 10.1097/00001622-200003000-00012. Curr Opin Oncol. 2000. PMID: 10750729 Review.

3

Direct analysis of tumor-associated peptide antigens.

Slingluff CL Jr, Hunt DF, Engelhard VH. Slingluff CL Jr, et al. Curr Opin Immunol. 1994 Oct;6(5):733-40. doi: 10.1016/0952-7915(94)90077-9. Curr Opin Immunol. 1994. PMID: 7530012 Review.

4

Tumor antigens and tumor vaccines: peptides as immunogens.

Slingluff CL Jr. Slingluff CL Jr. Semin Surg Oncol. 1996 Nov-Dec;12(6):446-53. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<446::AID-SSU10>3.0.CO;2-T. Semin Surg Oncol. 1996. PMID: 8914209 Review.

5

Immunity to melanoma antigens: from self-tolerance to immunotherapy.

Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Slingluff CL Jr, et al. Adv Immunol. 2006;90:243-95. doi: 10.1016/S0065-2776(06)90007-8. Adv Immunol. 2006. PMID: 16730266 Review.

6

Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms.

Slingluff CL. Slingluff CL. Cancer Immunol Immunother. 1999 Oct;48(7):371-3. doi: 10.1007/s002620050588. Cancer Immunol Immunother. 1999. PMID: 10501849 Free PMC article. Review.

7

gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.

Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ. Kierstead LS, et al. Br J Cancer. 2001 Nov 30;85(11):1738-45. doi: 10.1054/bjoc.2001.2160. Br J Cancer. 2001. PMID: 11742496 Free PMC article.

8

The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Slingluff CL Jr. Slingluff CL Jr. Cancer J. 2011 Sep-Oct;17(5):343-50. doi: 10.1097/PPO.0b013e318233e5b2. Cancer J. 2011. PMID: 21952285 Free PMC article. Review.

9

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.

Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, Merrill P, Fink R, Woodson EM, Wiernasz CJ, Patterson JW, Slingluff CL Jr. Chianese-Bullock KA, et al. J Immunol. 2005 Mar 1;174(5):3080-6. doi: 10.4049/jimmunol.174.5.3080. J Immunol. 2005. PMID: 15728523

10

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. Cox AL, et al. Science. 1994 Apr 29;264(5159):716-9. doi: 10.1126/science.7513441. Science. 1994. PMID: 7513441

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year